Aclaris Therapeutics, Inc.ACRSNASDAQ
LOADING
|||
Net Income Growth Accelerating
Trending higher, above historical average, slight contraction.
Left:
||||
Year-over-year net income growth rate
Latest
5.28%
↑ 109% above average
Average (39q)
-57.30%
Historical baseline
Range
High:94.90%
Low:-1172.77%
CAGR
-5.9%
Structural decline
| Period | Value |
|---|---|
| Q3 2025 | 5.28% |
| Q2 2025 | -2.28% |
| Q1 2025 | 84.38% |
| Q4 2024 | -1172.77% |
| Q3 2024 | 30.95% |
| Q2 2024 | 35.15% |
| Q1 2024 | -1036.22% |
| Q4 2023 | 94.90% |
| Q3 2023 | 1.04% |
| Q2 2023 | -5.00% |
| Q1 2023 | -1.90% |
| Q4 2022 | -38.51% |
| Q3 2022 | 2.82% |
| Q2 2022 | -9.28% |
| Q1 2022 | 17.61% |
| Q4 2021 | -7.84% |
| Q3 2021 | -16.44% |
| Q2 2021 | 36.84% |
| Q1 2021 | -118.28% |
| Q4 2020 | -23.59% |
| Q3 2020 | 8.09% |
| Q2 2020 | 25.59% |
| Q1 2020 | 16.18% |
| Q4 2019 | 66.39% |
| Q3 2019 | -10.91% |
| Q2 2019 | -32.77% |
| Q1 2019 | 2.56% |
| Q4 2018 | -17.75% |
| Q3 2018 | -4.88% |
| Q2 2018 | -3.27% |
| Q1 2018 | -31.81% |
| Q4 2017 | -26.07% |
| Q3 2017 | -22.60% |
| Q2 2017 | -18.15% |
| Q1 2017 | -9.45% |
| Q4 2016 | -7.30% |
| Q3 2016 | 16.91% |
| Q2 2016 | 1.29% |
| Q1 2016 | -176.60% |
| Q4 2015 | 55.67% |